Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (November 2016)
30 slides from Neurotech International's investor presentation, Nov 28, 2016
Slide 1: Improving the lives of people with neurological conditions
For personal use only Improving the lives of people with neurological conditions Investor Presentation Neurotech International Limited (ASX: NTI) | November - December 2016
Slide 2: Neurotech Overview
Neurotech Overview For personal use only Focussed on the development & commercialisation of regulated medical solutions for diagnosis & treatment of neurological disorders Innovative platform technology to enable medical practitioners to remotely monitor & play an active role in home-based thera
Slide 3: Operational Updates
Operational Updates For personal use only • Receipt of CE Marking for Mente Autism at end of Sep 16, enabling Mente Autism to be launched & marketed in Europe & other existing markets • Manufacturing of first batches of Mente Autism well advanced • Italy in-country registration & first shipments of
Slide 4: Capital Structure
Capital Structure For personal use only Capital Structure Share Price & Volume from Listing3 Ordinary Shares 88.0 m 0.60 12.0 ASX Closing Price (A$) Volume (m) Options 10.9 m Fully Diluted Capital1 98.9 m 0.50 10.0 Market capitalisation (at 25 November 2016) $41.4m Net pro forma cash position post I
Slide 5: Highly Experienced Board
Highly Experienced Board For personal use only Peter O’Connor • Deep experience in global funds management, asset allocation & manager selection advisory Chairman (Non-Exec) • Held senior public company directorships (UK, Canada & Australia) MA, Barrister-at Law • Non-executive director of Northern
Slide 6: Overview of Neurotech
For personal use only [x] Overview of
Slide 7: Market Positioning & Opportunity
Market Positioning & Opportunity For personal use only Medical Neurotechnology Clinical Grade Home Care • Understanding & influencing the brain & • Health care moving toward precision-based nervous system personal care • ‘Next frontier’ in medical science • Particularly for lifestyle disorders & chr
Slide 8: Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) For personal use only • ASD (or autism) is a lifelong development condition Standard treatments include1 • One in 68 children have some form of ASD Behaviour & • There is no cure, so the goal of every treatment is to: Educational Medication communication Neurofeedback
Slide 9: Current Mente Platform
Current Mente Platform For personal use only Clinical grade, medical device suitable for home use Monitor, review & interpret home based therapy data cloud Therapy delivered in comfort of patient’s home Personalise & alter Therapy data sent therapy as securely back to Clinic required Mente Cloud Hom
Slide 10: How Mente Autism works
How Mente Autism works For personal use only Mente Autism algorithm processes the Click for video link (opens external site) 4 waves & creates binaural beat representation Brainwaves are 3 recorded Algorithmically-generated 5 soundwaves are played Resulting benefits: • Improved 2 Run the Mente App c
Slide 11: Validation
Validation For personal use only • Neurofeedback stimulation for autism management has been around since the late 1990’s • Over 20 medical papers published on studies of baseload EEG profiles & brain imaging of ASD children, the efficacy of neurofeedback as a treatment form for ASD & other neurologi
Slide 12: 2015 Pilot Study
2015 Pilot Study1 For personal use only • 25 participant study of children diagnosed with autism as undertaken to test the efficacy of a four-channel Mente system • In people with autism, delta waves (normally associated with sleep) are abnormally high while alpha & beta waves (normally associated w
Slide 13: Mente Cloud EEG Database
Mente Cloud EEG Database Future value driver that will underpin the significant generation of knowledge in Neurotech, enable For personal use only continued improvements in existing therapy & drive development of future neurological therapies & solutions Performance tracking Daily session Deep data
Slide 14: US Clinical Trial Underway
US Clinical Trial Underway For personal use only • Double blind & independent clinical trial to be conducted in the US • 64 participant study, currently recruiting • Undertaken in conjunction with the Carrick Institute, Florida, United States • Institutional review board approval received from Unive
Slide 15: Certifications
Certifications For personal use only • Mente1 & Mente Autism both classified as a Class IIa medical device CE Marking • Regulated under the European Union Council Medical Device Directive 93/42/EEC • Mente1 listed as a Neurological Biofeedback Medical Device classified as Class 2 (special controls)
Slide 16: Sales Strategy – Three Key Pillars
Sales Strategy – Three Key Pillars For personal use only Target Markets Targeting Key Stakeholders Revenue Model • Italy – in country registrations currently being • Government & regulators – crucial to • Distributor / non-exclusive re-seller finalised, first delivery in December understanding any a
Slide 17: Product Bundling
Product Bundling For personal use only Complete Mente Autism Kit Optional Add-ons Pre-configured & locked tablet Remote support end-to-end Support Hotline Comprising headband, power supply, earphones, sensors, Quickguide, cloud system & ongoing updates. Sensors, earphones & power supply are availabl
Slide 18: First Target Consumer Market – Europe
First Target Consumer Market – Europe For personal use only United Kingdom Population: 65 million Target market: 32,500 Germany, Austria & Switzerland Populations: 98 million Target market: 49,000 Italy Population: 61 million Prevalence of autism: 1% 3-12 years target segment: 10% of autistic suffer
Slide 19: Italian Distribution Agreement
Italian Distribution Agreement For personal use only • First material exclusive Mente Autism distribution agreement signed • Through the distributor, Neurotech is working with key Italian in Dec 2015, delivery of first units expected by Dec 2016 stakeholders: • Covers Italy, includes an obligation t
Slide 20: Our Future
For personal use only Our Future
Slide 21: Platform
Platform Building Mente as a Platform for B2C & B2B users For personal use only Cutting-edge Hardware Clinical grade, medical device for Clinical grade, medical device clinical & research use suitable for home use Monitor, review & interpret home cloud Therapy delivered in comfort of patient’s based
Slide 22: Key Achievements & Next Milestones
Mente Pro & Mente Suite Launch Q4 2017 Key Achievements & Next Milestones For personal use only Mente Autism FDA Listing & TGA Approval 2017 2nd International Brain Stimulation Conference, Barcelona Q1 2017 Continuously reviewing & targeting new markets with Mente Autism & sales Mente Pro & Mente Su
Slide 23: Contact Details
Contact Details For personal use only Company Investor / Media Relations Wolfgang Storf, Chief Executive Officer Matthew Wright [email protected] [email protected] Neurotech International Ltd NWR Communications Level 14, 191 St Georges Terrace Level 7, 333 Collins St Perth Western
Slide 24: Appendices
For personal use only Appendices
Slide 25: The Evolution of Mente
The Evolution of Mente For personal use only Since its first release in Mente 2 Mente Autism Updated features: Updated features: 2013, Mente has been • Commercialised product • Clinical grade retail platform, enabling successfully taken from • Hypoallergenic & more ergonomic neurotech applications i
Slide 26: Mente Autism's Key Features
Mente Autism’s Key Features For personal use only • Safe & easy home use Light & portable, Mente has been designed for home use. It is safe & simple to activate, requires little to no direct supervision & does not restrict users & data collection to a clinical setting • Personalised therapy Mente Au
Slide 27: Collaborations & Awards
Collaborations & Awards Partnerships & collaborations with key neuroscience & neurotechnology research institutes are For personal use only key in the pursuit of continuous innovation & product excellence. Research Collaborations Awards The Company has received the following • University of Milan aw
Slide 28: Mente Testimonials
Mente Testimonials For personal use only “ I have a five year old daughter Jade. She is autistic & we have been using Mente for the past 10 & half months. We saw the first results after two weeks “ My son has been using Mente for the past two years. As he was diagnosed with ASD, we turned to Mente’s
Slide 29: Disclaimer
Disclaimer For personal use only This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements are not guarantees of Neurotech’s future performance and involved a number of risks and uncertainties that may cause actual results to differ
Slide 30: For personal use only
For personal use only www.neurotechinternational.com www.mentetech.com
Neurotech International — Investor Presentation (November 2016) on 6ix